PL2946785T3 - Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi - Google Patents
Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymiInfo
- Publication number
- PL2946785T3 PL2946785T3 PL15162630T PL15162630T PL2946785T3 PL 2946785 T3 PL2946785 T3 PL 2946785T3 PL 15162630 T PL15162630 T PL 15162630T PL 15162630 T PL15162630 T PL 15162630T PL 2946785 T3 PL2946785 T3 PL 2946785T3
- Authority
- PL
- Poland
- Prior art keywords
- diseases
- pharmacological chaperone
- predict response
- chaperone treatment
- treatment
- Prior art date
Links
- 108010006519 Molecular Chaperones Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2814108P | 2008-02-12 | 2008-02-12 | |
| US3568408P | 2008-03-11 | 2008-03-11 | |
| US9363108P | 2008-09-02 | 2008-09-02 | |
| US11349608P | 2008-11-11 | 2008-11-11 | |
| EP09710178.6A EP2252313B1 (en) | 2008-02-12 | 2009-02-12 | Method to predict response to pharmacological chaperone treatment of diseases |
| PCT/US2009/033963 WO2009102895A2 (en) | 2008-02-12 | 2009-02-12 | Method to predict response to pharmacological chaperone treatment of diseases |
| EP15162630.6A EP2946785B1 (en) | 2008-02-12 | 2009-02-12 | Method to predict response to pharmacological chaperone treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2946785T3 true PL2946785T3 (pl) | 2019-04-30 |
Family
ID=40957500
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09710178T PL2252313T3 (pl) | 2008-02-12 | 2009-02-12 | Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi |
| PL15162630T PL2946785T3 (pl) | 2008-02-12 | 2009-02-12 | Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi |
| PL18201960T PL3470077T3 (pl) | 2008-02-12 | 2009-02-12 | Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09710178T PL2252313T3 (pl) | 2008-02-12 | 2009-02-12 | Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18201960T PL3470077T3 (pl) | 2008-02-12 | 2009-02-12 | Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US8592362B2 (pl) |
| EP (4) | EP2946785B1 (pl) |
| JP (7) | JP5844045B2 (pl) |
| AU (7) | AU2009214648B2 (pl) |
| CA (1) | CA2715407C (pl) |
| CY (3) | CY1116466T1 (pl) |
| DK (3) | DK2252313T3 (pl) |
| ES (3) | ES2541933T3 (pl) |
| HR (3) | HRP20150728T1 (pl) |
| HU (3) | HUE042882T2 (pl) |
| LT (2) | LT3470077T (pl) |
| MX (1) | MX2010008835A (pl) |
| PL (3) | PL2252313T3 (pl) |
| PT (3) | PT2946785T (pl) |
| SI (3) | SI3470077T1 (pl) |
| WO (1) | WO2009102895A2 (pl) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE027569T2 (en) | 2006-05-16 | 2016-10-28 | Amicus Therapeutics Inc | Preparation for the treatment of Fabry disease |
| PL2252313T3 (pl) | 2008-02-12 | 2015-09-30 | Amicus Therapeutics Inc | Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi |
| AU2009223125A1 (en) * | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for Pompe disease |
| AR078498A1 (es) * | 2009-10-01 | 2011-11-09 | Baylor Res Inst | Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry |
| US20120283290A1 (en) * | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| PE20170906A1 (es) | 2014-09-30 | 2017-07-12 | Amicus Therapeutics Inc | Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados |
| JP6895892B2 (ja) * | 2015-03-19 | 2021-06-30 | トランスレイト バイオ， インコーポレイテッド | ポンペ病のｍＲＮＡ治療 |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| MX394968B (es) | 2015-12-30 | 2025-03-24 | Amicus Therapeutics Inc | Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe. |
| RS62212B1 (sr) | 2015-12-30 | 2021-09-30 | Amicus Therapeutics Inc | Augmentirana kiselina alfa-glukozidaza za lečenje pompeove bolesti |
| JP7098529B2 (ja) * | 2016-03-22 | 2022-07-11 | アミカス セラピューティックス インコーポレイテッド | Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法 |
| WO2017173060A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| CN109475607B (zh) | 2016-03-30 | 2022-04-26 | 阿米库斯治疗学公司 | 包含重组酸性α-葡糖苷酶的配制品 |
| MX2018011951A (es) * | 2016-03-30 | 2019-02-13 | Amicus Therapeutics Inc | Metodo para seleccionar proteinas recombinantes ricas en m6p. |
| US12070453B2 (en) | 2016-07-19 | 2024-08-27 | Amicus Therapeutics, Inc. | Treatment of Fabry disease in ERT-naïve and ERT-experienced patients |
| JP6546135B2 (ja) | 2016-08-24 | 2019-07-17 | 株式会社ノリタケカンパニーリミテド | 積層造形焼成体、積層造形焼成体の製造方法および積層造形焼成体製造用キット |
| IL266047B2 (en) * | 2016-10-20 | 2025-02-01 | Sangamo Therapeutics Inc | Methods and compositions for the treatment of fabry disease |
| EA202290114A1 (ru) * | 2017-03-30 | 2022-03-29 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| AU2018270925B2 (en) | 2017-05-15 | 2025-02-20 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase |
| PT3630114T (pt) | 2017-05-30 | 2024-02-01 | Amicus Therapeutics Inc | Migalastato para tratamento de pacientes com fabry com deficiência renal |
| CA3065298C (en) | 2017-05-30 | 2025-05-06 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| WO2019017938A1 (en) | 2017-07-19 | 2019-01-24 | Amicus Therapeutics, Inc. | TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES |
| ES2931054T3 (es) | 2017-08-28 | 2022-12-23 | Amicus Therapeutics Inc | Métodos para potenciar y/o estabilizar la función cardíaca en pacientes con enfermedad de Fabry |
| EP4717319A2 (en) | 2018-02-06 | 2026-04-01 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in pregnant patients |
| PT3749308T (pt) | 2018-02-06 | 2024-01-25 | Amicus Therapeutics Inc | Tratamento de pacientes com doença de fabry clássica com migalastato |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| SG11202101117QA (en) | 2018-08-20 | 2021-03-30 | Amicus Therapeutics Inc | Methods of treating fabry disease in patients having a mutation in the gla gene |
| NL2021840B1 (en) | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
| WO2020046132A1 (en) | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
| TW202042812A (zh) | 2019-01-22 | 2020-12-01 | 美商阿米庫斯醫療股份有限公司 | 減少法布瑞氏症患者中之腦血管事件之方法 |
| WO2020252129A1 (en) | 2019-06-11 | 2020-12-17 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having renal impairment |
| JP2021024864A (ja) * | 2019-08-07 | 2021-02-22 | アミカス セラピューティックス インコーポレイテッド | Ｇｌａ遺伝子に突然変異を有する患者のファブリー病を治療する方法 |
| CA3149955A1 (en) | 2019-09-06 | 2021-03-11 | Kumar DHANASEKHARAN | Method for capturing and purification of biologics |
| SI4114390T1 (sl) * | 2020-03-06 | 2025-03-31 | Amicus Therapeutics, Inc. | Postopki zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| US20240293387A1 (en) | 2021-07-12 | 2024-09-05 | Amicus Therapeutics, Inc. | Methods of Treating Fabry Disease in Pediatric Patients |
| US20260041744A1 (en) | 2022-05-05 | 2026-02-12 | Amicus Therapeutics, Inc. | Methods for Treating Pompe Disease |
| JP2025540119A (ja) | 2022-12-02 | 2025-12-11 | アミカス セラピューティックス インコーポレイテッド | 小児患者の遅発型ポンペ病の治療方法 |
| JP2025540135A (ja) | 2022-12-02 | 2025-12-11 | アミカス セラピューティックス インコーポレイテッド | 小児患者の乳児発症型ポンペ病の治療方法 |
| US20240197706A1 (en) | 2022-12-13 | 2024-06-20 | Amicus Therapeutics, Inc. | Methods of improving the pharmacokinetics of migalastat |
| WO2026006625A1 (en) | 2024-06-26 | 2026-01-02 | Amicus Therapeutics, Inc. | Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21381A (en) * | 1858-08-31 | Bracelet | ||
| US270486A (en) * | 1883-01-09 | Bundle-separating attachment for self-binding harvesters | ||
| US203019A (en) * | 1878-04-30 | Improvement in circuits for acoustic or telephonic telegraphs | ||
| US264467A (en) * | 1882-09-19 | Chables h | ||
| US3586908A (en) | 1969-02-28 | 1971-06-22 | Robert E Vosteen | Automatic potential control system for electrophotography apparatus |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| AU734905B2 (en) | 1996-04-10 | 2001-06-28 | Regents Of The University Of California, The | Correction of genetic defects using chemical chaperones |
| US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US6244113B1 (en) | 1999-10-29 | 2001-06-12 | University Of Alabama In Huntsville | Method and apparatus for measuring microgravity acceleration |
| US7842470B2 (en) * | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
| EP1896083B1 (en) * | 2005-05-17 | 2016-03-02 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| WO2008045015A1 (en) | 2005-06-08 | 2008-04-17 | Amicus Therapeutics, Inc. | Imino and amino sugar purification |
| AU2006254796B2 (en) * | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| WO2007089591A2 (en) * | 2006-01-27 | 2007-08-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for high throughput screening of pharmacological chaperones |
| HUE027569T2 (en) | 2006-05-16 | 2016-10-28 | Amicus Therapeutics Inc | Preparation for the treatment of Fabry disease |
| DK1860101T3 (da) | 2006-05-24 | 2011-07-25 | Amicus Therapeutics Inc | Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| JP2010525084A (ja) | 2007-04-26 | 2010-07-22 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いたリソソーム蓄積症治療のための投薬計画 |
| PL2252313T3 (pl) | 2008-02-12 | 2015-09-30 | Amicus Therapeutics Inc | Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi |
| WO2010048532A1 (en) | 2008-10-24 | 2010-04-29 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| US20110070643A1 (en) | 2009-05-26 | 2011-03-24 | Do Hung V | Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics |
| US9206457B2 (en) | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| CA2781277C (en) | 2009-11-17 | 2018-01-09 | Baylor Research Institute | Urinary triaosylceramide (gb3) as a marker of cardiac disease |
| MX2013010446A (es) | 2011-03-11 | 2014-03-27 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de la enfermedad de fabry. |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| CA2917995C (en) | 2012-07-17 | 2021-01-26 | Amicus Therapeutics, Inc. | Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation |
| JP7098529B2 (ja) | 2016-03-22 | 2022-07-11 | アミカス セラピューティックス インコーポレイテッド | Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法 |
| US12070453B2 (en) | 2016-07-19 | 2024-08-27 | Amicus Therapeutics, Inc. | Treatment of Fabry disease in ERT-naïve and ERT-experienced patients |
| WO2018132471A1 (en) | 2017-01-10 | 2018-07-19 | Amicus Therapeutics, Inc. | Recombinant alpha-galactosidase a for treatment of fabry disease |
| CA3065298C (en) | 2017-05-30 | 2025-05-06 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| WO2019017938A1 (en) | 2017-07-19 | 2019-01-24 | Amicus Therapeutics, Inc. | TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES |
| ES2931054T3 (es) | 2017-08-28 | 2022-12-23 | Amicus Therapeutics Inc | Métodos para potenciar y/o estabilizar la función cardíaca en pacientes con enfermedad de Fabry |
| EP4717319A2 (en) | 2018-02-06 | 2026-04-01 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in pregnant patients |
| PT3749308T (pt) | 2018-02-06 | 2024-01-25 | Amicus Therapeutics Inc | Tratamento de pacientes com doença de fabry clássica com migalastato |
| SG11202101117QA (en) | 2018-08-20 | 2021-03-30 | Amicus Therapeutics Inc | Methods of treating fabry disease in patients having a mutation in the gla gene |
| WO2020252129A1 (en) | 2019-06-11 | 2020-12-17 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having renal impairment |
| JP2021024864A (ja) | 2019-08-07 | 2021-02-22 | アミカス セラピューティックス インコーポレイテッド | Ｇｌａ遺伝子に突然変異を有する患者のファブリー病を治療する方法 |
-
2009
- 2009-02-12 PL PL09710178T patent/PL2252313T3/pl unknown
- 2009-02-12 HU HUE15162630A patent/HUE042882T2/hu unknown
- 2009-02-12 DK DK09710178.6T patent/DK2252313T3/en active
- 2009-02-12 LT LTEP18201960.4T patent/LT3470077T/lt unknown
- 2009-02-12 PL PL15162630T patent/PL2946785T3/pl unknown
- 2009-02-12 ES ES09710178.6T patent/ES2541933T3/es active Active
- 2009-02-12 SI SI200932099T patent/SI3470077T1/sl unknown
- 2009-02-12 PT PT15162630T patent/PT2946785T/pt unknown
- 2009-02-12 PT PT97101786T patent/PT2252313E/pt unknown
- 2009-02-12 LT LTEP15162630.6T patent/LT2946785T/lt unknown
- 2009-02-12 MX MX2010008835A patent/MX2010008835A/es active IP Right Grant
- 2009-02-12 JP JP2010546901A patent/JP5844045B2/ja active Active
- 2009-02-12 PL PL18201960T patent/PL3470077T3/pl unknown
- 2009-02-12 EP EP15162630.6A patent/EP2946785B1/en active Active
- 2009-02-12 DK DK15162630.6T patent/DK2946785T3/en active
- 2009-02-12 SI SI200931229T patent/SI2252313T1/sl unknown
- 2009-02-12 HR HRP20150728TT patent/HRP20150728T1/hr unknown
- 2009-02-12 HU HUE18201960A patent/HUE051377T2/hu unknown
- 2009-02-12 EP EP18201960.4A patent/EP3470077B1/en active Active
- 2009-02-12 AU AU2009214648A patent/AU2009214648B2/en active Active
- 2009-02-12 SI SI200931920T patent/SI2946785T1/sl unknown
- 2009-02-12 CA CA2715407A patent/CA2715407C/en active Active
- 2009-02-12 EP EP09710178.6A patent/EP2252313B1/en active Active
- 2009-02-12 HU HUE09710178A patent/HUE026543T2/hu unknown
- 2009-02-12 ES ES15162630T patent/ES2716502T3/es active Active
- 2009-02-12 ES ES18201960T patent/ES2836121T3/es active Active
- 2009-02-12 DK DK18201960.4T patent/DK3470077T3/da active
- 2009-02-12 PT PT182019604T patent/PT3470077T/pt unknown
- 2009-02-12 EP EP20192637.5A patent/EP3824900A1/en active Pending
- 2009-02-12 WO PCT/US2009/033963 patent/WO2009102895A2/en not_active Ceased
-
2010
- 2010-08-12 US US12/855,468 patent/US8592362B2/en not_active Ceased
- 2010-08-20 US US12/860,611 patent/US20110152319A1/en not_active Abandoned
-
2013
- 2013-10-15 US US14/054,369 patent/US9095584B2/en active Active
-
2014
- 2014-09-10 AU AU2014221321A patent/AU2014221321B2/en active Active
- 2014-12-02 JP JP2014244283A patent/JP2015091239A/ja active Pending
-
2015
- 2015-06-05 US US14/731,603 patent/US9545397B2/en active Active
- 2015-07-08 CY CY20151100595T patent/CY1116466T1/el unknown
-
2016
- 2016-03-01 JP JP2016039171A patent/JP6672013B2/ja active Active
- 2016-07-20 AU AU2016206297A patent/AU2016206297A1/en not_active Abandoned
- 2016-09-19 US US15/268,662 patent/US20170003301A1/en not_active Abandoned
-
2017
- 2017-11-30 AU AU2017268649A patent/AU2017268649A1/en not_active Abandoned
-
2018
- 2018-07-26 US US16/046,247 patent/US10813921B2/en active Active
- 2018-12-17 US US16/222,305 patent/USRE48608E1/en active Active
- 2018-12-27 JP JP2018245609A patent/JP6837469B2/ja active Active
-
2019
- 2019-01-22 HR HRP20190143TT patent/HRP20190143T1/hr unknown
- 2019-01-24 CY CY20191100100T patent/CY1121386T1/el unknown
- 2019-08-20 AU AU2019219727A patent/AU2019219727B2/en active Active
-
2020
- 2020-10-26 US US17/079,859 patent/US20250082621A9/en active Pending
- 2020-11-17 HR HRP20201827TT patent/HRP20201827T1/hr unknown
- 2020-11-25 CY CY20201101114T patent/CY1123816T1/el unknown
-
2021
- 2021-02-09 JP JP2021019383A patent/JP7277493B2/ja active Active
- 2021-08-20 AU AU2021218172A patent/AU2021218172A1/en not_active Abandoned
-
2023
- 2023-05-08 JP JP2023076515A patent/JP2023109807A/ja not_active Withdrawn
-
2024
- 2024-09-24 AU AU2024219997A patent/AU2024219997A1/en active Pending
-
2025
- 2025-06-11 JP JP2025097940A patent/JP2025148351A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190143T1 (hr) | Postupak za predviđanje odgovora na liječenje bolesti farmakološkim šaperonom | |
| IL219051A0 (en) | Methods to predict clinical outcome of cancer | |
| IL209855A0 (en) | Supression of neuroedocrine diseases | |
| EP2496176A4 (en) | ENTZELLULARISIERUNGSVERFAHREN | |
| PT2435825E (pt) | Métodos para o tratamento de doenças | |
| ZA201109278B (en) | Method for treatment of diseases | |
| EP2517095A4 (en) | ABOUT STORAGE HANDLING | |
| EP2464376A4 (en) | METHOD FOR REPAIRING NERVE DENDING | |
| PT2504698T (pt) | Método para prever a resposta de uma doença oncológica a uma medida terapêutica | |
| FR2945911B1 (fr) | Procede de traitement contre l'ambroisie |